NO324725B1 - MORT-1-protein, DNA-sekvens som koder for MORT-1 og antistoffer spesifikke for MORT-1, samt fremgangsmate for fremstilling, farmasoytiske sammensetninger og anvendelser. - Google Patents

MORT-1-protein, DNA-sekvens som koder for MORT-1 og antistoffer spesifikke for MORT-1, samt fremgangsmate for fremstilling, farmasoytiske sammensetninger og anvendelser. Download PDF

Info

Publication number: NO324725B1
Authority: NO; Norway
Prior art keywords: protein; mort; fas; cells; proteins
Prior art date: 1994-12-15

Application number

NO19972716A

Other languages

English (en)

Norwegian (no)

Other versions

NO972716D0 (no

NO972716L (no

Inventor

David Wallach

Mark Boldin

Igor Mett

Eugene Varfolomeev

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-15

Filing date

1997-06-12

Publication date

2007-12-03

1994-12-15 Priority claimed from IL11200294A external-priority patent/IL112002A0/xx

1995-02-19 Priority claimed from IL112692A external-priority patent/IL112692A/en

1995-07-16 Priority claimed from IL11461595A external-priority patent/IL114615A0/xx

1997-06-12 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1997-06-12 Publication of NO972716D0 publication Critical patent/NO972716D0/no

1997-07-11 Publication of NO972716L publication Critical patent/NO972716L/no

2007-12-03 Publication of NO324725B1 publication Critical patent/NO324725B1/no

Links

108010077716 Fas-Associated Death Domain Protein Proteins 0.000 title claims description 70
102000010579 Fas-Associated Death Domain Protein Human genes 0.000 title claims description 69
238000000034 method Methods 0.000 title claims description 60
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
108090000623 proteins and genes Proteins 0.000 claims abstract description 137
102000004169 proteins and genes Human genes 0.000 claims abstract description 132
239000013598 vector Substances 0.000 claims abstract description 51
238000012258 culturing Methods 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 172
102000005962 receptors Human genes 0.000 claims description 57
230000027455 binding Effects 0.000 claims description 44
230000003834 intracellular effect Effects 0.000 claims description 43
239000002299 complementary DNA Substances 0.000 claims description 42
239000003446 ligand Substances 0.000 claims description 40
230000014509 gene expression Effects 0.000 claims description 28
239000012634 fragment Substances 0.000 claims description 20
241000700605 Viruses Species 0.000 claims description 17
239000000284 extract Substances 0.000 claims description 17
239000000523 sample Substances 0.000 claims description 16
108020004414 DNA Proteins 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 14
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
230000008569 process Effects 0.000 claims description 13
210000004881 tumor cell Anatomy 0.000 claims description 13
230000002900 effect on cell Effects 0.000 claims description 11
238000000338 in vitro Methods 0.000 claims description 10
238000002955 isolation Methods 0.000 claims description 10
238000010367 cloning Methods 0.000 claims description 9
102000000844 Cell Surface Receptors Human genes 0.000 claims description 8
108010001857 Cell Surface Receptors Proteins 0.000 claims description 8
238000001042 affinity chromatography Methods 0.000 claims description 8
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 7
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 7
238000001086 yeast two-hybrid system Methods 0.000 claims description 7
102000018697 Membrane Proteins Human genes 0.000 claims description 6
108010052285 Membrane Proteins Proteins 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 6
238000002105 Southern blotting Methods 0.000 claims description 4
230000036961 partial effect Effects 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
239000012504 chromatography matrix Substances 0.000 claims description 2
238000000605 extraction Methods 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
230000004481 post-translational protein modification Effects 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
101150028668 APO1 gene Proteins 0.000 abstract description 3
108010052621 fas Receptor Proteins 0.000 description 132
102000018823 fas Receptor Human genes 0.000 description 131
235000018102 proteins Nutrition 0.000 description 108
108020003175 receptors Proteins 0.000 description 52
108060008682 Tumor Necrosis Factor Proteins 0.000 description 45
230000000694 effects Effects 0.000 description 45
102000003390 tumor necrosis factor Human genes 0.000 description 40
102000037865 fusion proteins Human genes 0.000 description 28
108020001507 fusion proteins Proteins 0.000 description 28
102000010170 Death domains Human genes 0.000 description 24
108050001718 Death domains Proteins 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 22
239000000427 antigen Substances 0.000 description 22
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 20
108091007433 antigens Proteins 0.000 description 20
102000036639 antigens Human genes 0.000 description 20
102000003298 tumor necrosis factor receptor Human genes 0.000 description 20
102100039556 Galectin-4 Human genes 0.000 description 19
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 19
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 19
230000011664 signaling Effects 0.000 description 19
230000004068 intracellular signaling Effects 0.000 description 18
238000003556 assay Methods 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
230000003993 interaction Effects 0.000 description 15
230000001404 mediated effect Effects 0.000 description 15
238000011534 incubation Methods 0.000 description 14
239000007790 solid phase Substances 0.000 description 14
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
230000004568 DNA-binding Effects 0.000 description 12
239000004098 Tetracycline Substances 0.000 description 12
229960002180 tetracycline Drugs 0.000 description 12
229930101283 tetracycline Natural products 0.000 description 12
235000019364 tetracycline Nutrition 0.000 description 12
150000003522 tetracyclines Chemical class 0.000 description 12
102000014914 Carrier Proteins Human genes 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 11
238000000211 autoradiogram Methods 0.000 description 11
108091008324 binding proteins Proteins 0.000 description 11
230000030833 cell death Effects 0.000 description 11
230000001472 cytotoxic effect Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
230000035772 mutation Effects 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
101150064015 FAS gene Proteins 0.000 description 10
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 10
230000001413 cellular effect Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
230000006870 function Effects 0.000 description 10
238000001114 immunoprecipitation Methods 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
238000010396 two-hybrid screening Methods 0.000 description 10
102000053642 Catalytic RNA Human genes 0.000 description 9
108090000994 Catalytic RNA Proteins 0.000 description 9
230000004913 activation Effects 0.000 description 9
230000000445 cytocidal effect Effects 0.000 description 9
231100000433 cytotoxic Toxicity 0.000 description 9
230000003013 cytotoxicity Effects 0.000 description 9
231100000135 cytotoxicity Toxicity 0.000 description 9
238000001514 detection method Methods 0.000 description 9
229960004452 methionine Drugs 0.000 description 9
230000033458 reproduction Effects 0.000 description 9
108091092562 ribozyme Proteins 0.000 description 9
102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 8
108060001084 Luciferase Proteins 0.000 description 8
239000005089 Luciferase Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000011324 bead Substances 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
238000013519 translation Methods 0.000 description 8
102100023995 Beta-nerve growth factor Human genes 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
102000005720 Glutathione transferase Human genes 0.000 description 7
108010070675 Glutathione transferase Proteins 0.000 description 7
108010025020 Nerve Growth Factor Proteins 0.000 description 7
210000004899 c-terminal region Anatomy 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000004927 fusion Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
101150066555 lacZ gene Proteins 0.000 description 7
239000000047 product Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000001890 transfection Methods 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 6
238000013459 approach Methods 0.000 description 6
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
-1 factors Proteins 0.000 description 6
239000000499 gel Substances 0.000 description 6
108020003519 protein disulfide isomerase Proteins 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000010276 construction Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
108010031345 placental alkaline phosphatase Proteins 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000035899 viability Effects 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
230000004186 co-expression Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000034994 death Effects 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
239000012133 immunoprecipitate Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
102100026693 FAS-associated death domain protein Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
231100000354 acute hepatitis Toxicity 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000012636 effector Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000013198 immunometric assay Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
238000001466 metabolic labeling Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
108091006106 transcriptional activators Proteins 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
102100032303 26S proteasome non-ATPase regulatory subunit 2 Human genes 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
101000835846 Arabidopsis thaliana Sucrose nonfermenting 4-like protein Proteins 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
101710127053 FAS-associated death domain protein Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
101150009006 HIS3 gene Proteins 0.000 description 2
101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
102000047715 human FAS Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000000869 mutational effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
KTPDNYVWXJTUKG-UHFFFAOYSA-O 1-methyl-2-[2-(2-phenyl-1h-indol-3-yl)ethenyl]quinolin-1-ium Chemical compound C1=CC2=CC=CC=C2[N+](C)=C1\C=C\C(C1=CC=CC=C1N1)=C1C1=CC=CC=C1 KTPDNYVWXJTUKG-UHFFFAOYSA-O 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
101710180366 CDP-L-myo-inositol myo-inositolphosphotransferase Proteins 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
101710104316 Cell surface-binding protein Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
101150055709 SNF1 gene Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000005558 fluorometry Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
244000062804 prey Species 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
238000003158 yeast two-hybrid assay Methods 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transmitters (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Radar Systems Or Details Thereof (AREA)

NO19972716A 1994-12-15 1997-06-12 MORT-1-protein, DNA-sekvens som koder for MORT-1 og antistoffer spesifikke for MORT-1, samt fremgangsmate for fremstilling, farmasoytiske sammensetninger og anvendelser. NO324725B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IL11200294A IL112002A0 (en)	1994-05-11	1994-12-15	Modulatiors of tnf/ngf superfamily receptors, their preparation and use
IL112692A IL112692A (en)	1995-02-19	1995-02-19	ANTIBODIES TO PROTEIN WHICH BINDS TO Fas-R
IL11461595A IL114615A0 (en)	1995-07-16	1995-07-16	Modulators of the function of fas receptors and other proteins
PCT/US1995/016542 WO1996018641A1 (en)	1994-12-15	1995-12-14	Modulators of the function of fas/apo1 receptors

Publications (3)

Publication Number	Publication Date
NO972716D0 NO972716D0 (no)	1997-06-12
NO972716L NO972716L (no)	1997-07-11
NO324725B1 true NO324725B1 (no)	2007-12-03

Family

ID=27271687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972716A NO324725B1 (no)	1994-12-15	1997-06-12	MORT-1-protein, DNA-sekvens som koder for MORT-1 og antistoffer spesifikke for MORT-1, samt fremgangsmate for fremstilling, farmasoytiske sammensetninger og anvendelser.

Country Status (18)

Country	Link
EP (1)	EP0871645B1 (fi)
JP (1)	JP3787355B2 (fi)
KR (1)	KR100536394B1 (fi)
CN (1)	CN1105725C (fi)
AT (1)	ATE377073T1 (fi)
AU (1)	AU706401B2 (fi)
CA (1)	CA2207815C (fi)
CY (1)	CY2586B2 (fi)
DE (1)	DE69535634T2 (fi)
DK (1)	DK0871645T3 (fi)
ES (1)	ES2292172T3 (fi)
FI (1)	FI121273B (fi)
HK (1)	HK1007248A1 (fi)
MX (1)	MX9704501A (fi)
NO (1)	NO324725B1 (fi)
PT (1)	PT871645E (fi)
UA (1)	UA58489C2 (fi)
WO (1)	WO1996018641A1 (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL114615A0 (en) *	1995-07-16	1995-11-27	Yeda Res & Dev	Modulators of the function of fas receptors and other proteins
US6060238A (en) *	1995-02-13	2000-05-09	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US7097972B1 (en)	1995-02-13	2006-08-29	Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US6015665A (en) *	1995-02-13	2000-01-18	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
AU755662B2 (en) *	1995-02-22	2002-12-19	Yeda Research And Development Co. Ltd.	Modulators of regulatory proteins
EP0813419B8 (en) *	1995-02-22	2005-08-24	Yeda Research & Development Company, Ltd.	Modulators of regulatory proteins
US6747138B1 (en)	1995-04-03	2004-06-08	Regents Of The University Of Michigan	Methods and compositions for regulating Fas-associated apoptosis
US7807783B1 (en)	1995-04-03	2010-10-05	The Regents Of The University Of Michigan	Methods and compositions for regulating FAS-associated apoptosis
US6399327B1 (en)	1995-07-16	2002-06-04	Yeda Research And Development Co. Ltd.	Modulators of the function of FAS receptors and other proteins
US6911526B2 (en) *	1996-07-22	2005-06-28	The Trustees Of Columbia University In The City Of New York	Compounds that inhibit the interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
EP0842665A3 (en) *	1996-11-14	2002-12-18	Smithkline Beecham Corporation	Interleukin-1 beta converting enzyme like apoptotic proteases and their agonists
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
JP2001522247A (ja) *	1997-04-25	2001-11-13	アメリカン・ホーム・プロダクツ・コーポレイション	ニューロンｍｏｒｔ１イソ形態
WO1999000499A1 (en) *	1997-06-26	1999-01-07	Chiron Corporation	Human fadd-interacting protein (fip)
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US6015712A (en) *	1999-07-19	2000-01-18	Isis Pharmaceuticals Inc.	Antisense modulation of FADD expression
EA010594B1 (ru)	2001-05-24	2008-10-30	Займодженетикс, Инк.	Слитые белки taci-иммуноглобулина
US6743630B2 (en)	2002-03-06	2004-06-01	The Trustees Of Columbia University In The City Of New York	Method of preparing a protein array based on biochemical protein-protein interaction
AU2006278227B2 (en)	2005-08-09	2011-10-20	Ares Trading S.A.	Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
CA2618765A1 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for treating b-cell malignancies using taci-ig fusion molecule
UA98462C2 (ru)	2006-05-15	2012-05-25	Арес Трейдинг С.А.	Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO178777C (no) *	1994-05-09	1996-05-29	Kvaerner Eng	Varmeveksler
US7807783B1 (en) *	1995-04-03	2010-10-05	The Regents Of The University Of Michigan	Methods and compositions for regulating FAS-associated apoptosis
US5674734A (en) *	1995-05-18	1997-10-07	President And Fellows Of Harvard College	Cell death protein

1995
- 1995-12-14 AU AU46022/96A patent/AU706401B2/en not_active Expired
- 1995-12-14 UA UA97063391A patent/UA58489C2/uk unknown
- 1995-12-14 PT PT95944148T patent/PT871645E/pt unknown
- 1995-12-14 JP JP51932496A patent/JP3787355B2/ja not_active Expired - Lifetime
- 1995-12-14 EP EP95944148A patent/EP0871645B1/en not_active Expired - Lifetime
- 1995-12-14 KR KR1019970703992A patent/KR100536394B1/ko not_active IP Right Cessation
- 1995-12-14 CN CN95196789A patent/CN1105725C/zh not_active Expired - Lifetime
- 1995-12-14 ES ES95944148T patent/ES2292172T3/es not_active Expired - Lifetime
- 1995-12-14 WO PCT/US1995/016542 patent/WO1996018641A1/en active IP Right Grant
- 1995-12-14 AT AT95944148T patent/ATE377073T1/de active
- 1995-12-14 DE DE69535634T patent/DE69535634T2/de not_active Expired - Lifetime
- 1995-12-14 CA CA2207815A patent/CA2207815C/en not_active Expired - Lifetime
- 1995-12-14 DK DK95944148T patent/DK0871645T3/da active
- 1995-12-14 MX MX9704501A patent/MX9704501A/es active IP Right Grant
1997
- 1997-06-10 FI FI972457A patent/FI121273B/fi not_active IP Right Cessation
- 1997-06-12 NO NO19972716A patent/NO324725B1/no not_active IP Right Cessation
1998
- 1998-06-24 HK HK98106458A patent/HK1007248A1/xx not_active IP Right Cessation
2007
- 2007-11-20 CY CY0700017A patent/CY2586B2/xx unknown

Also Published As

Publication number	Publication date
JP3787355B2 (ja)	2006-06-21
NO972716D0 (no)	1997-06-12
PT871645E (pt)	2007-11-14
UA58489C2 (uk)	2003-08-15
EP0871645A1 (en)	1998-10-21
EP0871645B1 (en)	2007-10-31
DE69535634T2 (de)	2008-08-28
KR100536394B1 (ko)	2006-04-21
FI972457A (fi)	1997-06-10
CY2586B2 (en)	2009-11-04
FI121273B (fi)	2010-09-15
CA2207815C (en)	2011-03-29
NO972716L (no)	1997-07-11
AU4602296A (en)	1996-07-03
CA2207815A1 (en)	1996-06-20
AU706401B2 (en)	1999-06-17
MX9704501A (es)	1997-10-31
DK0871645T3 (da)	2007-12-03
ATE377073T1 (de)	2007-11-15
ES2292172T3 (es)	2008-03-01
WO1996018641A1 (en)	1996-06-20
FI972457A0 (fi)	1997-06-10
EP0871645A4 (en)	1999-11-24
DE69535634D1 (de)	2007-12-13
JPH10510712A (ja)	1998-10-20
CN1105725C (zh)	2003-04-16
CN1169729A (zh)	1998-01-07
HK1007248A1 (en)	1999-04-09

Legal Events

Date	Code	Title	Description
2015-12-21	MK1K	Patent expired

Publication	Publication Date	Title
US20070166787A1 (en)	2007-07-19	Modulators of regulatory proteins
NO324725B1 (no)	2007-12-03	MORT-1-protein, DNA-sekvens som koder for MORT-1 og antistoffer spesifikke for MORT-1, samt fremgangsmate for fremstilling, farmasoytiske sammensetninger og anvendelser.
JP3980641B2 (ja)	2007-09-26	Ｆａｓ受容体およびほかのタンパク質の機能のモジュレーター
NO321514B1 (no)	2006-05-15	DNA-sekvens som koder for modulatorer for TNF/NGF superfamiliereseptorer, samt protein, farmasoytisk sammensetning, vektor, fremgangsmater og anvendelser derav.
JP3860608B2 (ja)	2006-12-20	調節タンパク質のモジュレーター
NO327054B1 (no)	2009-04-14	Polypeptid som bindes til TRAF2, samt fremgangsmate for fremstilling og isolering og identifisering derav og DNA-sekvens, vektor, transformerte eukaryote eller prokariote vertsceller, antistoffer, farmasoytisk sammensetning anvendelse derav.
WO1996018641A9 (en)	1996-08-22	Modulators of the function of fas/apo1 receptors
IL109632A (en)	2007-03-08	Modulators of the function of tnf receptors
JP4351389B2 (ja)	2009-10-28	Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質
EP1058691A1 (en)	2000-12-13	Caspase-8 interacting proteins
US7323548B2 (en)	2008-01-29	Modulators of the function of FAS/APO1 receptors
US7108999B1 (en)	2006-09-19	Modulators of the function of FAS/AP01 receptors
AU755662B2 (en)	2002-12-19	Modulators of regulatory proteins
RU2241747C2 (ru)	2004-12-10	Молекула днк, кодирующая полипептид, способный связываться с внутриклеточным доменом рецептора лиганда fas(fas-ic), полипептид, способ его получения, вектор, способ модуляции действия лиганда fas-r на клетки (варианты), фармацевтическая композиция (варианты), спрособ выделения и идентификации белка
AU2003200969B2 (en)	2007-11-01	Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
AU5133296A (en)	1996-09-11	Modulators of regulatory proteins
IL112692A (en)	2012-01-31	ANTIBODIES TO PROTEIN WHICH BINDS TO Fas-R
EP1454985A2 (en)	2004-09-08	Modulators of receptors of the tnf/ngf receptor family
IL126428A (en)	2010-02-17	Modulators of tnf receptor associated factor (traf), their preparation and use
AU3508101A (en)	2001-06-21	Modulators of TNF receptor associated factor (TRAF), their preparation and use